Skip to main content
Contact us
Evidence

Demonstrated safety and efficacy in MOSAIC, a randomized clinical trial in patients undergoing Mohs surgery.

Tempo’s first-in-human study compared MAP™ with standard care in patients with full-thickness wounds after Mohs surgery for non-melanoma skin cancer.

MOSAIC I
Design
Randomized, controlled, multicenter
Patients
40
Setting
Full-thickness wounds after Mohs surgery for non-melanoma skin cancer
Control
Hydrocolloid standard of care
Safety
Met the primary safety endpoint, with no serious adverse device effects, infections or delayed wound healing reported
Registry
NCT06600152
  • Safetyprimary endpoint met
  1. Day 0

    Surgery and MAP™ applied

  2. Healing
    14days earlier

    to a favorable wound bed score

  3. Follow-up
    6months

    improved physician-assessed scar quality

Source for the clinical programme summary: Tempo Therapeutics, September 23, 2026 ↗. Clinical outcomes are reported study results, not guaranteed treatment effects.
MOSAIC I · Six-month outcomes and care

Improved scar quality, fewer interventions

At about six months, MAP™-treated wounds showed significantly better physician-assessed scar quality and less soft tissue volume loss than standard hydrocolloid care.

Silver nitrate needed
MAP™ 11.5%
Control 64.3%
Hypergranulation
MAP™ 7.7%
Control 50.0%

Each dot represents about 5% of patients; dot counts are rounded to the nearest 5%. Figures from Tempo’s August 2026 company presentation.

Samuel Broder, M.D.
Clinical perspective
“Mohs surgery can be lifesaving, but the healing process—and concerns about scarring—can be difficult for patients. There remains a substantial need for new approaches that help restore tissue after cancer removal. Tempo’s MAP™ technology, being evaluated in the MOSAIC study, offers a promising approach to addressing that need. For dermatologic surgeons, the goal extends beyond removing the cancer: it is also about giving patients a softer landing through healing and recovery.”Samuel Broder, M.D.Director, National Cancer Institute (retired)
MOSAIC II · NIH funded

The next randomized study.

MOSAIC II will evaluate whether MAP™ reduces the time needed to develop a wound bed suitable for grafting after complex non-melanoma skin cancer resections with exposed bone. It is supported by an SBIR award from the National Cancer Institute of approximately $2.25 million over two years. Principal investigator: Stephanie Deshayes, PhD.

Source for the clinical programme summary: Tempo Therapeutics, September 23, 2026 ↗. Clinical outcomes are reported study results, not guaranteed treatment effects.